Get the Stockscreener App
2.285
2.97%
-0.075
Cel-Sci Corp. stock is traded at $2.285, with a volume of 89,501.
It is down -2.97% in the last 24 hours and down -69.00% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$2.36
Open:
$2.4
24h Volume:
89,501
Relative Volume:
0.65
Market Cap:
$11.74M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-4.4804
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
+9.05%
1M Performance:
-69.00%
6M Performance:
-84.73%
1Y Performance:
-94.04%
1-Day Range:
$2.25
$2.40
1-Week Range:
$1.98
$2.78
52-Week Range:
$1.98
$66.60
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
2.285 | 7.40M | 0 | -26.92M | -18.92M | -0.51 |
|
ONC
Beone Medicines Ltd Adr
|
256.94 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.77 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.70 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
496.02 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CVM stock touches 52-week low at $2.32 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $2.32 amid sharp annual decline - Investing.com Australia
CEL-SCI Closes $5 Million Public Offering - marketscreener.com
Cancer Immunotherapy Firm CEL-SCI Secures $5M Funding to Advance Multikine Treatment - Stock Titan
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
Dow Moves Higher; US Initial Jobless Claims Fall - Benzinga
CEL-SCI (CVM) Prices Public Offering Amid Stock Slump - GuruFocus
CEL-SCI Prices Offering of 2 Million Shares - marketscreener.com
CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Applicati - GuruFocus
CVM Stock Offering Priced Below Previous Closing Value | CVM Sto - GuruFocus
Cel-Sci Says Prices Public Offering Of 2 Million Shares At $2.50 Per Share - marketscreener.com
CEL-SCI Raises $5M in New Stock Offering: Cancer Immunotherapy Program Multikine Gets Fresh Funding - Stock Titan
CVM stock touches 52-week low at $4.67 amid sharp annual decline By Investing.com - Investing.com South Africa
CEL-SCI Announces Planned Public Offering; Shares Fall After Hours - marketscreener.com
CEL-SCI announces public stock offering to fund cancer therapy By Investing.com - Investing.com Canada
CEL-SCI Corporation (CVM) Plans Public Offering for R&D and Corporate Needs | CVM Stock News - GuruFocus
CEL-SCI announces public stock offering to fund cancer therapy - Investing.com
CEL-SCI Announces Strategic Public Offering: Cancer Immunotherapy Development Gets Major Funding Push - Stock Titan
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - BioSpace
CVM stock touches 52-week low at $4.67 amid sharp annual decline - Investing.com Canada
CEL-SCI Completes Saudi Breakthrough Medicine Designation Application for Multikine Cancer Drug - marketscreener.com
CEL-SCI seeks SFDA nod for cancer drug Multikine By Investing.com - Investing.com Canada
CEL-SCI seeks SFDA nod for cancer drug Multikine - Investing.com
CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Application in Saudi Arabia | CVM Stock News - GuruFocus
Revolutionary Cancer Drug Shows 73% Survival Rate, Nears Fast-Track Approval in Saudi Arabia - Stock Titan
CEL-SCI Implements 1-for-30 Stock Split To Support Share Price - Nasdaq
CEL-SCI approves 1-for-30 stock combination By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Approves 1-for-30 Stock Consolidation | CVM Stock News - GuruFocus
CEL-SCI approves 1-for-30 stock combination - Investing.com Australia
CEL-SCI's Board Approves 1-for-30 Share Combination - marketscreener.com
CEL-SCI Announces Combination of Common Stock | CVM Stock News - GuruFocus
CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20 - TipRanks
CEL-SCI Plans Major 1:30 Reverse Split as CEO Hints at Upcoming Catalysts - Stock Titan
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results | C - GuruFocus
CEL-SCI Cancer Drug Shows 95% Quality of Life Success in Phase 3 Trial | CVM Stock News - Stock Titan
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Business Wire
Cel-Sci: Fiscal Q2 Earnings Snapshot - New Haven Register
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World
LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News
Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News
A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com
Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com
CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com
Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com
Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Applied Dna Sciences Inc (APDN)’s Financial Health - DWinneX
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
3.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):